Arena Pharmaceuticals, Inc. ARNA
Set alert
99.99 +99.99 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -13.10
- Beta
- 0.55
- Short ratio
- 5.79
- Inst. own
- 83.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 4, 2022
- 50-d avg
- 93.49
- 200-d avg
- 70.91
- 1y target
- 97.86
Analyst view
Consensus: hold
Hold
Price target (mean) 97.86 -2.1% downside
Now 99.99
- Target (low)
- 80.00
- Target (mean)
- 97.86
- Target (high)
- 105.00
Ratings (0m) 7 4 buy · 3 hold · 0 sell
- Strong buy2
- Buy2
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 13
- 2 months ago 13
- 3 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -1.98 | 0.0% | 20.00K | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -2.40 | 0.0% | 20.00K | -97.5% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 14.14M | +26085.2% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 115.03M | +713.5% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 9, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Dec 21, 2021 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Dec 14, 2021 | Citigroup | Downgrade | Buy | Neutral |
| Dec 14, 2021 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Dec 14, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Dec 14, 2021 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Dec 14, 2021 | Credit Suisse | Downgrade | Outperform | Neutral |
| Dec 14, 2021 | Jefferies | Downgrade | Buy | Hold |
| Dec 13, 2021 | Needham | Downgrade | Buy | Hold |
| Dec 8, 2021 | Wells Fargo | Initiated | — | Overweight |
| Aug 10, 2021 | Cantor Fitzgerald | Maintained | — | Overweight |
| Aug 6, 2021 | Credit Suisse | Maintained | — | Outperform |
| May 18, 2021 | Goldman Sachs | Initiated | — | Buy |
| May 7, 2021 | SVB Leerink | Maintained | — | Outperform |
| Apr 27, 2021 | Citigroup | Initiated | — | Buy |
| Apr 13, 2021 | Credit Suisse | Maintained | — | Outperform |
| Mar 26, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 3, 2021 | Cantor Fitzgerald | Maintained | — | Overweight |
| Feb 24, 2021 | SVB Leerink | Maintained | — | Outperform |
| Nov 19, 2020 | SMBC Nikko | Initiated | — | Outperform |
| Nov 10, 2020 | SVB Leerink | Maintained | — | Outperform |
| Sep 30, 2020 | B of A Securities | Maintained | — | Buy |
| Aug 6, 2020 | Wells Fargo | Maintained | — | Overweight |
| Aug 6, 2020 | SVB Leerink | Maintained | — | Outperform |
| Jul 27, 2020 | Citigroup | Maintained | — | Buy |
| Jun 29, 2020 | HC Wainwright & Co. | Initiated | — | Buy |
| May 22, 2020 | Jefferies | Maintained | — | Buy |
| May 18, 2020 | Jefferies | Initiated | — | Buy |
| May 8, 2020 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Mar 31, 2020 | Guggenheim Securities | Initiated | — | Buy |